Clinical Connection Home
  Welcome To
Clinical Connection
 
Be notified of new studies!
Attention-Deficit Hyperactivity Disorder Clinical Trials, Diagnosis, and Treatment
Thank you for your interest in clinical trials for Attention-Deficit Hyperactivity Disorder.

Please click "Search" to find Attention-Deficit Hyperactivity Disorder clinical trials and medical research studies or read below for information on Attention-Deficit Hyperactivity Disorder diagnosis and treatment.

If you receive too many study listings you may enter your zip code to find the locations closest to you.


Any Of These Words:
OR
All Of These Words
OR
This Exact Phrase:
AND
Zip Code:
Distance:
Search results will appear below.
Your search returned 23 studies:


ADHD in Children and Adolescents - Chapel Hill NC
ADHD - Las Vegas NV
Adolescent ADHD - Clementon NJ
Adolescent ADHD - Willingboro NJ
Adolescent ADHD - Philadelphia PA
Attention Deficit Hyperactivity Disorder (ADHD) - Portland OR
ADHD in Children and Adolescents - NATIONWIDE
ADHD in Children and Adolescents - Houston TX
ADHD in Children and Adolescents - Baltimore MD
ADHD in Children and Adolescents - Clementon NJ
ADHD in Children and Adolescents - North Miami FL
ADHD in Children and Adolescents - San Diego CA
ADHD in Children and Adolescents - Bradenton FL
ADHD in Children and Adolescents - Cleveland OH
ADHD in Children and Adolescents - Irvine CA
ADHD in Children and Adolescents - Lake Jackson TX
ADHD in Children and Adolescents - Oklahoma City OK
ADHD in Children and Adolescents - Chapel Hill NC
ADHD in Children and Adolescents - St. Louis MO
ADHD in Children and Adolescents - Little Rock AR
ADHD in Children and Adolescents - Miami FL
ADHD in Children and Adolescents - El Centro CA
ADHD and Insomnia - Las Vegas NV
Browse All Available Clinical Trials

Join Now to be Notified of New Clinical Trials

View Information and Clinical Trials for Other Conditions


Attention-Deficit Hyperactivity Disorder

Attention-deficit hyperactivity disorder (ADHD) previously known as Attention Deficit Disorder (ADD), is generally considered to be a developmental disorder, largely neurological in nature, affecting about 5% of the world's population. The disorder typically presents itself during childhood, and is characterized by a persistent pattern of inattention and/or hyperactivity, as well as forgetfulness, poor impulse control or impulsivity, and distractibility. ADHD is currently considered to be a persistent and chronic condition for which no medical cure is available. ADHD is most commonly diagnosed in children and, over the past decade, has been increasingly diagnosed in adults. About 60% of children diagnosed with ADHD retain the disorder as adults. Studies show that there is a familial transmission of the disorder which does not occur through adoptive relationships. Twin studies indicate that the disorder is highly heritable and that genetics contribute about three quarters of the total ADHD population. While the majority of ADHD is believed to be genetic in nature, roughly 1/5 of all ADHD cases are thought to be acquired after conception due to brain injury caused by either toxins or physical trauma prenatally or postnatally. According to a majority of medical research in the United States, as well as other countries, ADHD is today generally regarded as a chronic disorder for which there are some effective treatments. Over 200 controlled studies have shown that stimulant medication is an effective way to treat ADHD. Methods of treatment usually involve some combination of medication, behaviour modification, life style changes, and counseling. Certain social critics are highly skeptical that the diagnosis denotes a genuine impairment and question virtually all that is known about ADHD. The symptoms of ADHD are not as profoundly different from normal behavior as are those of other chronic mental disorders. Still, ADHD has been shown to often impair functioning, and many adverse life outcomes are associated with ADHD.

Current Research

For current research articles click - here

Classification

ADHD is a developmental disorder that is often said to be neurological in nature. The term "developmental" means that certain traits such as impulse control significantly lag in development when compared to the general population. This developmental lag has been estimated to range between 30-40 percent in ADHD sufferers in comparison to their peers; consequently these delayed attributes are considered an impairment. ADHD has also been classified as a behavior disorder and a neurological disorder or combinations of these classifications such as neurobehavioural or neurodevelopmental disorders. These compounded terms are now more frequently used in the field to describe the disorder. The behavioral classification for ADHD is not completely accurate in that those with Predominately Inattentive ADHD often display few or no overt behaviors.

Diagnosis

Based on DSM-IV criteria, three types of ADHD are identified:
  1. ADHD, Combined Type: if both criteria 1A and 1B are met for the past 6 months
  2. ADHD Predominantly Inattentive Type: if criterion 1A is met but criterion 1B is not met for the past six months
  3. ADHD, Predominantly Hyperactive-Impulsive Type: if Criterion 1B is met but Criterion 1A is not met for the past six months.

ICD

In the tenth edition of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) the symptoms of ADHD are given the name "Hyperkinetic disorders". When a conduct disorder (as defined by ICD-10) is present, the condition is referred to as "Hyperkinetic conduct disorder". Otherwise the disorder is classified as "Disturbance of Activity and Attention", "Other Hyperkinetic Disorders" or "Hyperkinetic Disorders, Unspecified". The latter is sometimes referred to as, "Hyperkinetic Syndrome".

The American Academy of Pediatrics Clinical Practice Guideline for children with ADHD emphasizes that a reliable diagnosis is dependent upon the fulfillment of three criteria:
  • The use of explicit criteria for the diagnosis using the DSM-IV-TR.
  • The importance of obtaining information about the child’s symptoms in more than one setting.
  • The search for coexisting conditions that may make the diagnosis more difficult or complicate treatment planning.
The first criterion can be satisfied by using an ADHD-specific instrument such as the Conners' Rating Scale. The second criterion is best fulfilled by examining the individual's history. This history can be obtained from parents and teachers, or a patient's memory. The requirement that symptoms be present in more than one setting is very important because the problem may not be with the child, but instead with teachers or parents who are too demanding. The use of intelligence testing, psychological testing, and neuropsychological testing (to satisfy the third criterion) is essential in order to find or rule out other factors that might be causing or complicating the problems experienced by the patient.

The Centers for Disease Control and Prevention (CDC) state that a diagnosis of ADHD should only be made by trained health care providers, as many of the symptoms may also be part of other conditions, such as bodily illness or other physiological disorders, such as hyperthyroidism. It is not uncommon that physically and mentally nonpathological individuals exhibit at least some of the symptoms from time to time. Severity and pervasiveness of the symptoms leading to prominent functional impairment across different settings (school, work, social relationships) are major factors in a positive diagnosis.

Adults often continue to be impaired by ADHD. Adults with ADHD are diagnosed under the same criteria, including the stipulation that their symptoms must have been present prior to the age of seven. Adults face some of their greatest challenges in the areas of self-control and self-motivation, as well as executive functioning, usually having more symptoms of inattention and fewer of hyperactivity or impulsiveness than children do.

Common comorbid conditions are Oppositional Defiance Disorder (ODD). About 20% to 25% of children with ADHD meet criteria for a learning disorder. Learning disorders are more common when there are inattention symptoms.

Causes

The exact cause of ADHD remains unknown and in all probability ADHD is a heterogeneous disorder, meaning that several causes could create very similar symptomology. Still, there is a wide body of evidence which indicates that the overriding cause of ADHD is genetics. Research suggests that a large majority of ADHD arises from a combination of various genes, many of which affect dopamine transporters. Suspect genes include the 10-repeat allele of the DAT1 gene, the 7-repeat allele of the DRD4 gene, and the dopamine beta hydroxylase gene (DBH TaqI). Additionally, SPECT scans found people with ADHD to have reduced blood circulation, and a significantly higher concentration of dopamine transporters in the striatum which is in charge of planning ahead.

A study by the U.S. Department of Energy’s Brookhaven National Laboratory in collaboration with Mount Sinai School of Medicine in New York suggest that it is not the dopamine transporter levels that indicate ADHD, but the brain's ability to produce dopamine itself. The study was done by injecting 20 ADHD subjects and 25 control subjects with a radiotracer that attaches itself to dopamine transporters. The study found that it was not the transporter levels that indicated ADHD, but the dopamine itself. ADHD subjects showed lower levels of dopamine across the board. They speculated that since ADHD subjects had lower levels of dopamine to begin with, the number of transporters in the brain was not the telling factor. In support of this notion, plasma homovanillic acid, an index of dopamine levels, was found to be inversely related not only to childhood ADHD symptoms in adult psychiatric patients, but to "childhood learning problems" in healthy subjects as well.

An early PET scan study found that global cerebral glucose metabolism was 8.1% lower in medication-naive adults who had been diagnosed as ADHD while children. The image on the right illustrates glucose metabolism in the brain of a 'normal' adult while doing an assigned auditory attention task; the image on the right illustrates the areas of activity in the brain of an adult who had been diagnosed with ADHD as a child when given that same task; these are not pictures of individual brains, which would contain substantial overlap, these are images constructed to illustrate group-level differences. Additionally, the regions with the greatest deficit of activity in the ADHD patients (relative to the controls) included the premotor cortex and the superior prefrontal cortex. A second study in adolescents failed to find statistically significant differences in global glucose metabolism between ADHD patients and controls, but did find statistically significant deficits in 6 specific regions of the brains of the ADHD patients (relative to the controls). Most notably, lower metabolic activity in one specific region of the left anterior frontal lobe was significantly inversely correlated with symptom severity. These findings strongly imply that lowered activity in specific regions of the brain, rather than a broad global deficit, is involved in ADHD symptoms. However, these readings are of subjects doing an assigned task. They could be found in ADHD diagnosed patients because they simply were not attending to the task. Hence the parts of the brain used by others doing the task would not show equal activity in the ADHD patients.

The estimated contribution of non genetic factors to the contribution of all cases of ADHD is 20 percent. The environmental factors implicated are common exposures and include alcohol, in utero tobacco smoke and lead exposure. Lead concentration below the Center for Disease Control's action level account for slightly more cases of ADHD than tobacco smoke (290 000 versus 270 000, in the USA, ages 4 to 15). Complications during pregnancy and birth—including premature birth—might also play a role. It has been observed that women who smoke while pregnant are more likely to have children with ADHD. This could be related to the fact that nicotine is known to cause hypoxia (lack of oxygen) in utero, but it could also be that ADHD women have more probabilities to smoke both in general and during pregnancy, being more likely to have children with ADHD due to genetic factors. Head injuries can cause a person to present ADHD-like symptoms, possibly because of damage done to the patient's frontal lobes. Because these types of symptoms can be attributable to brain damage, the earliest designation for ADHD was "Minimal Brain Damage".

There is no compelling evidence that social factors alone can create ADHD. Many researchers believe that attachments and relationships with caregivers and other features of a child's environment have profound effects on attentional and self-regulatory capacities. It is noteworthy that a study of foster children found that an inordinate number of them had symptoms closely resembling ADHD. An editorial in a special edition of Clinical Psychology in 2004 stated that "our impression from spending time with young people, their families and indeed colleagues from other disciplines is that a medical diagnosis and medication is not enough. In our clinical experience, without exception, we are finding that the same conduct typically labelled ADHD is shown by children in the context of violence and abuse, impaired parental attachments and other experiences of emotional trauma." Furthermore, Complex Post Traumatic Stress Disorder can result in attention problems that can look like ADHD, as can Sensory Integration Disorders.

Despite the lack of evidence that nutrition causes ADHD, studies have found that malnutrition is correlated with attention deficits.

Treatment

There are several clinically proven effective options available to treat people diagnosed with ADHD. ADHD is treated most effectively, and cost efficiently, with medication. Psychotherapy is another option, with or without medication Omega-3 fatty acids, zinc, and magnesium may have benefits with regards to ADHD symptoms.

Comorbid disorders or substance abuse can make finding the proper diagnosis and the right overall treatment more costly and time-consuming.

Prognosis

ADHD is a developmental disorder meaning that certain traits will be delayed in the ADHD individual. These traits will develop but just at a much slower rate than the average person. With ADHD it has been estimated that this lag could be as high as thirty to forty percent in the development of impulse control. Symptoms of ADHD are often seen by the time a child enters preschool. Those with ADHD typically have a greater degree of parent-child conflict and emotional reactivity. The incidence of speech problems, central auditory processing difficulties, and coordination problems are all higher than that of the general population. A marked decrease in academic skills such as reading, spelling, or math is common with children who have ADHD.

During the elementary years an ADHD student will have more difficulties with work completion, productivity, planning, remembering things needed for school, and meeting deadlines. Oppositional and socially aggressive behaviour is seen in 40-70 percent of children at this age. Even ADHD kids with average to above average intelligence show "chronic and severe underachievement". Fully 46% of those with ADHD have been suspended and 11% expelled. Thirty seven percent of those with ADHD do not get a high school diploma even though many of them will receive special education services. The combined outcomes of the expulsion and dropout rates indicate that almost half of all ADHD students never finish highschool. Only five percent of those with ADHD will get a college degree compared to twenty seven percent of the general population. (US Census, 2003)

Social impairment for those with ADHD are seen at both school and work. They often have more troubled relationships with peers or family members. At the workplace they change jobs more often and are more likely to get fired. Their income level does not rise as quickly as their peers even when education level, IQ, and their neighborhood is accounted for. Thirty five percent of all those with ADHD will be self employed in their mid-thirties. Those with ADHD are at greater risk of: injury, abnormal risk taking, smoking, having learning disabilities, other mental disorders, teen pregnancy, substance abuse, involvement with the criminal justice system, and having a poorer driving record.

Prevention

There is no known way to prevent ADHD. Some studies indicate an association between mothers who smoke during pregnancy and a higher rate of ADHD in their children. Avoiding smoking, alcohol, and drugs during pregnancy may help prevent a higher risk of developing ADHD or similar behaviour in offspring.

Epidemiology

ADHD's prevalence worldwide is estimated to be a bit over 5%, with most of the reported variability being due to methodological characteristics of studies. 10% of males, and (only) 4% of females have been diagnosed in the U.S. This apparent sex difference may reflect either a difference in susceptibility or that females with ADHD are less likely to be diagnosed than males.

History

Some sources claim to have identified historical and literary references to ADHD before 1900, however, the condition we refer to as "ADHD" dates to the mid-twentieth century, when physicians developed a diagnosis for a set of conditions variously referred to as "minimal brain damage", "learning/behavioural disabilities" or "hyperactivity".

In 493 BC, physician-scientist Hippocrates described a condition that seems to be compatible with what we now know as ADHD. He described patients who had "quickened responses to sensory experience, but also less tenaciousness because the soul moves on quickly to the next impression". Hippocrates attributed this condition to an "overbalance of fire over water”. His remedy for this "overbalance" was "barley rather than wheat bread, fish rather than meat, water drinks, and many natural and diverse physical activities." Shakespeare made reference to a "malady of attention", in King Henry VIII. In 1845, Dr. Heinrich Hoffmann (a German physician and poet who wrote books on medicine and psychiatry) became interested in writing for children when he couldn't find suitable materials to read to his 3-year-old son. The result was a book of poems, complete with illustrations, about children and their undesirable behaviours. "Die Geschichte vom Zappel-Philipp" (The Story of Fidgety Philip) in Der Struwwelpeter was a description of a little boy who could be interpreted as having attention deficit hyperactivity disorder, or as merely a moral fable to amuse young children and encourage them to behave properly.

In 1902 the English pediatrician George Still gave a series of lectures to the Royal College of Physicians in England, and described a condition which some have claimed is analogous to ADHD. Still described a group of children with significant behavioral problems, caused, he believed, by an innate hereditary dysfunction and not by poor child rearing or environment. However, analysis of Still's descriptions by Palmer and Finger indicated that the qualities Still described are not "considered primary symptoms of ADHD".

The 1918–1919 influenza pandemic left many survivors with encephalitis, affecting their neurological functions. Some of these exhibited immediate behavioral problems which may correspond to ADHD (although no diagnosis for such a disorder existed at the time). This caused many later commentators to believe that the condition was the result of injury rather than heredity. The concept of hyperactivity not being caused by brain damage was first described by Stella Chess as, ""Hyperactive Child Syndrome" in 1960. This caused a significant rift in the understanding of the disorder. Europeans saw hyperkinesis as unusual and often associated it with retardation, brain damage, and conduct disorders, and changes to the ICD were not made until 1994. In the USA by 1966, following observations that the condition existed without any objectively observed pathological disorder or injury, researchers changed the terminology from Minimal Brain Damage to Minimal Brain Dysfunction.

In 1937 a Dr. Bradley in Providence, RI reported that a group of children with behavioral problems improved after being treated with stimulant medication. In 1957 the stimulant methylphenidate (Ritalin) became available. In its various forms (Ritalin, Focalin, Concerta, Metadate, and Methylin), it remains one of the most widely prescribed medications for ADHD. Ritalin was first produced in 1950. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use. In 1975 Pemoline (Cylert) was approved by the FDA for use in the treatment of ADHD. While an effective agent for managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to dissolve hourly across an 8–12 hour period (Medadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge across an 8–12 hour period after ingestion (Concerta). In 2003 – Atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug to be used specifically for ADHD. In 2007 Lisdexamfetamine becomes the first prodrug to receive FDA approval for ADHD. The landmark study of 1999 – The largest study of treatment for ADHD in history – is published in the American Journal of Psychiatry. Known as the Multimodal Treatment Study of ADHD (MTA Study), it involved more than 570 children with ADHD at 6 sites in the United States and Canada randomly assigned to 4 treatment groups. Results generally showed that medication alone was more effective than psychosocial treatments alone, but that their combination was beneficial for some subsets of ADHD children beyond the improvement achieved only by medication. More than 40 studies have subsequently been published from this massive dataset.

Psychiatry first codified a condition called “hyperkinetic reaction of childhood” in 1968, displaying the psychoanalytical influences of that time. The name Attention Deficit Disorder (ADD) was first introduced in DSM-III, the 1980 edition. By 1987 – The DSM-IIIR was released changing the diagnosis to "Undifferentiated Attention Deficit Disorder." Further revisions to the DSM were made in 1994 – DSM-IV described three groupings within ADHD, which can be simplified as: mainly inattentive; mainly hyperactive-impulsive; and both in combination. During 1996, ADHD accounted for at least 40% of child psychiatry references.

Controversy

The ADHD diagnosis has been questioned on many fronts. Some critics focus upon the positive traits that people with ADHD are thought to have, such as "hyperfocusing." Others believe ADHD is a divergent or normal-variant human behavior (using the term neurodiversity to describe this idea), emphasizing that human behaviour is immensely variable and "ADHD" may simply represent one part of the spectrum. Such critics sometimes allege that ADHD is not actually a discrete condition and question why it should be treated with drugs. Others dispute the alleged genetic basis of ADHD.


(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Adhd)





Findings From Current Research

Genetic and Environmental Contributions to Retrospectively Reported DSM-IV Childhood Attention Deficit Hyperactivity Disorder

Authors: Haberstick BC, Timberlake D, Hopfer CJ, Lessem JM, Ehringer MA, Hewitt JK.

Department of Psychiatry, University of Colorado Health Science Center, Denver, CO, USA.

BACKGROUND: A variety of methodologies and techniques converge on the notion that adults and children with attention deficit hyperactivity disorder (ADHD) have similar deficits, but there is limited knowledge about whether adult retrospective reports reflect similar genetic and environmental influences implicated in childhood ADHD.MethodDSM-IV ADHD symptoms were collected retrospectively from 3896 young adults participating in the National Longitudinal Study of Adolescent Health. Responses from this genetically informative sample of same- and opposite-sex twins and siblings were used to determine the magnitude of genetic and environmental influences. Possible gender differences in these effects were also examined. The degree of familial specificity of the genetic and environmental influences on the Inattentive and Hyperactive-Impulsive symptom dimensions was also determined. RESULTS: Additive genetic effects contributed moderately to DSM-IV Inattentive, Hyperactive-Impulsive and Combined ADHD subtypes (heritability estimates of 0.30-0.38). Individual-specific influences accounted for the remaining proportion of the variance. Both genetic and individual-specific environmental effects contributed to the covariation of Inattentive and Hyperactive-Impulsive symptomologies. CONCLUSIONS: Results from our genetic analyses agree with previous findings based on self-assessment of current and retrospectively reported ADHD symptoms in adolescents and adults. Large individual-specific environmental influences as identified here suggest that current questionnaires used for retrospective diagnoses may not provide the most accurate reconstruction of the etiological influences on childhood ADHD in general population samples.

Journal: Psychol Med. 2007 Sep 25;:1-10
Adapted from PubMed; click here to access full journal article.




The Consequences of Attention-Deficit/Hyperactivity Disorder in Adults

Authors: Goodman DW.

GOODMAN: Johns Hopkins at Green Spring Station, Lutherville, MD.

Until recently, attention-deficit/hyperactivity disorder (ADHD) was a diagnosis reserved for children and adolescents as it was believed to dissipate before adulthood. New evidence, however, supports the persistence of ADHD beyond adolescence, and it is now recognized as a chronic neurobehavioral disorder in adults. Adults with ADHD have difficulties with school, work, family interactions, and social activities. Although treatments are available for adult ADHD, many patients never receive an accurate diagnosis that would afford them appropriate therapeutic intervention. If left untreated, adult ADHD can cause significant personal, social, and economic burdens that can have a negative impact on overall quality of life. This article discusses how ADHD presents in adults and the effects of the disorder on educational, occupational, interpersonal, and social functioning. Currently available treatments for ADHD in adults are also reviewed.

Journal: J Psychiatr Pract. 2007 Sep;13(5):318-27.
Adapted from PubMed; click here to access full journal article.




Emerging Drugs for Attention-Deficit/Hyperactivity Disorder

Authors: Weisler RH.

Duke University Medical Center, Durham, NC, USA. rweisler@aol.com

Symptoms of attention-deficit/hyperactivity disorder (ADHD) are heterogeneous and often accompanied by comorbid psychiatric disorders. Although symptoms tend to lessen with age, many patients continue to be affected by the disorder into adulthood. Although many medications are available to treat ADHD, it is unlikely that a single medication will ever be developed to work for all patients. Recent advances, such as long-acting, extended-release formulations and transdermal delivery systems, have lengthened the duration of effectiveness, which has increased compliance and eliminated the need for additional medication dosing during the school or work day. Additional safe, well-tolerated, long-acting medications with further reduced potential for diversion and abuse are needed. Catecholamine pathways and their effect on executive functions and ADHD symptom control have been productive areas of research. Potential therapies such as adrenergic receptor agonists, glutamatergic agents, GABA receptor antagonists and nicotine receptor agonists are being explored as future pharmacotherapies for ADHD.

Journal: Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
Adapted from PubMed; click here to access full journal article.




Continuity in Methylphenidate Treatment of Adults with Attention-Deficit/Hyperactivity Disorder

Authors: Olfson M, Marcus SC, Zhang HF, Wan GJ.

BACKGROUND: Although stimulant therapy is commonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapy remain largely unknown. OBJECTIVE: To (1) compare the continuity of methylphenidate (MPH) therapy among adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2) examine some of the methodological issues involved in research with administrative claims for ADHD. METHODS: An analysis of pharmacy and medical claims for 75 US managed care plans representing approximately 55 million beneficiaries for dates of service from January 1, 2000 through December 31, 2004. Patients had to be adults (aged 18 to 64 years) who had 1 or more outpatient medical claims for ADHD (International Classification of Diseases, Ninth Revision, Clinical Modification code 314.xx) during the study period and who had initiated ER-MPH or IR-MPH treatment for ADHD. The study cohorts did not have a pharmacy claim for MPHs, amphetamines, pemoline, or atomoxetine for 6 months preceding the first (index) MPH pharmacy claim. Stimulant treatment episodes were defined to start on the index date and terminate on the last date supplied of the index medication. Episodes of treatment were also defined as terminated if there was a gap of e30 days between the end of the days supplied on the pharmacy claim and the date of the next pharmacy claim for the index medication. RESULTS: Less than one third (30.0%) of the adult patients who were prescribed MPH had 1 or more medical claims with a diagnosis code for ADHD. For the adult MPH patients with at least 1 medical claim with a diagnosis code for ADHD, the patients who initiated therapy with ER-MPH (N = 2,833) were significantly younger, were more likely to be male, and were less likely to be treated by a psychiatrist than were the patients who initiated therapy with IR-MPH (N = 2,289). Only 50.5% (n =1,156) of IR-MPH patients and 61.4% (n =1,739) of ER-MPH patients had more than 1 pharmacy claim for the index MPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the index medication (ER-MPH: 68 days, 95% confidence interval (CI), 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age, gender, treatment by a psychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergency mental health treatment, and inpatient mental health care, ER-MPH initiation was associated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio: 1.27, 95% CI, 1.20-1.35). CONCLUSION: In management of adult ADHD, use of ER-MPH formulations was associated with a longer median duration of the initially prescribed medication than was use of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length of therapy is clinically important.

Journal: J Manag Care Pharm. 2007 Sep;13(7):570-7.
Adapted from PubMed; click here to access full journal article.




Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)

Authors: Matza LS, Johnston JA, Faries DE, Malley KG, Brod M.

Center for Health Outcomes Research at UBC, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD, 20814, USA, louis.matza@unitedbiosource.com.

AIMS: This study examined responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL), which was developed to assess health-related quality of life (HRQL) among adults with attention-deficit/hyperactivity disorder (ADHD). METHODS: Adults with ADHD completed the AAQoL, Conners' Adult ADHD Rating Scale (CAARS), SF-36, and Endicott Work Productivity Scale (EWPS) at baseline and week 8 of a randomized, placebo-controlled trial of atomoxetine. Clinicians rated symptom severity and improvement (CGI-ADHD-S, CGI-ADHD-I). Responsiveness was examined through effect sizes and association with change in the measures listed previously (Spearman correlations, GLMs). RESULTS: Analyses included 328 patients (58.8% male; mean age = 36.9 years). All AAQoL scales reflected significant improvement from baseline to week 8 (P < 0.0001). AAQoL change scores were significantly correlated with change in the CGI-ADHD-S (r = -0.37 to -0.50), EWPS (r = -0.43 to -0.63), and CAARS (r = -0.35 to -0.62) (all P < 0.001). AAQoL change scores significantly discriminated among patients with various levels of symptom improvement. AAQoL effect sizes (-0.67 to -1.11) were larger than effect sizes for the SF-36 (0.15 to -0.39). CONCLUSIONS: The AAQoL was responsive to change in symptoms of ADHD, and it appears to be a useful outcome measure for treatments of ADHD in adults.

Journal: Qual Life Res. 2007 Sep 12
Adapted from PubMed; click here to access full journal article.




Symptom Exaggeration by College Adults in Attention-Deficit Hyperactivity Disorder and Learning Disorder Assessments

Authors: Sullivan BK, May K, Galbally L.

Counseling and Substance Abuse Services, College of Charleston, Charleston, South Carolina, USA.

To test the hypothesis that sub-optimal effort detected by one popular symptom validity measure, the Word Memory Test (WMT), should be interpreted as symptom exaggeration, the authors examined attention-deficit hyperactivity disorder (ADHD) and learning disorder (LD) assessment data collected from healthy adult patients over the past four years at one mid-size Southeastern college. They conducted six tests of this hypothesis, drawing upon extant research. Rates of apparent symptom exaggeration comparable to those found in medicolegal settings (e.g., personal injury cases), particularly in the context of ADHD evaluations, were found. WMT scores were positively correlated with intellectual and neurocognitive test scores, and negatively correlated with self-report symptom inventory scores. Measures of negative response bias embedded in one common self-report measure of psychopathology (the Personality Assessment Inventory) were not correlated with WMT performance. Unattended WMT administrations led to somewhat higher failure rates than were found when the examiners were present in the room during all phases of the test's administration. In light of considerable secondary gain motives in this population, the authors conclude that poor effort as evidenced by low WMT scores implies symptom exaggeration and not other factors in these assessments. The routine inclusion of empirically supported symptom validity measures in these evaluations is recommended, and future research directions are suggested.

Journal: Appl Neuropsychol. 2007;14(3):189-207.
Adapted from PubMed; click here to access full journal article.




Retrospective Ratings of ADHD Symptoms Made at Young Adulthood by Clinic-Referred Boys with ADHD-Related Problems, Their Brothers without ADHD, and Control Participants

Authors: Loney J, Ledolter J, Kramer JR, Volpe RJ.

Department of Pediatrics, University of Iowa.

Retrospective childhood attention-deficit/hyperactivity disorder (ADHD) symptoms are required to diagnosis adult ADHD, but the validity of self-rated symptoms across time is questionable. Here, boys with ADHD-related problems, their brothers without ADHD, and former schoolmates rated themselves during young adulthood for ages 9, 14, and 19. Brothers rated probands retrospectively at the same ages. The young adults referred as children for ADHD (a) acknowledged childhood symptoms; (b) described improvement over time; (c) did not differ from brothers or controls on most self-ratings of young adult symptoms; (d) rated themselves as more symptomatic at age 9, but less symptomatic at age 19, than their brothers rated them; and (e) agreed only to some degree with brothers' ratings of probands' aggression (median correlation = .22). Probands' ratings showed limited agreement with judges' symptom ratings (median correlation = .16) and young adult follow-up examiners' ratings (median correlation = .14). These findings are not accounted for solely by changes in informants, nor by the course of ADHD psychopathology. They suggest some stability but limited internal consistency and validity for retrospective ADHD ratings by probands and brothers.

Journal: Psychol Assess. 2007 Sep;19(3):269-80.
Adapted from PubMed; click here to access full journal article.




Join Now - Become a free member and get notified about studies in your area when they become available.

Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.

View Information and Clinical Trials for Other Conditions - Access all of our health-related content.
Depression - Virginia Beach VA
in Virginia Beach, VA


Hypertension (High Blood Pressure) - Sacramento CA
in Carmichael, CA


Migraine - Virginia Beach VA
in Virginia Beach, VA


Bipolar Depression - Norristown PA
in Norristown, PA


Depression - Norristown PA
in Norristown, PA


Adolescent Depression - Virginia Beach VA
in Virginia Beach, VA


Major Depression - New York NY
in New York, NY


Bipolar Depression - New York NY
in New York, NY


Generalized Anxiety Disorder - New York NY
in New York, NY


Are You Ready to Quit Smoking? - Menlo Park CA
in Menlo Park, CA


Psoriasis - Baltimore MD
in Baltimore, MD


Migraine- Virginia Beach VA
in Virginia Beach, VA


ADHD in Children and Adolescents - Chapel Hill NC
in Chapel Hill, NC


Eczema (Atopic Dermatitis) - NATIONWIDE
in NATIONWIDE,


Osteoarthritis - Virginia Beach VA
in Virginia Beach, VA


Genital Warts - NATIONWIDE
in NATIONWIDE,


Diabetic Neuropathy - DeLand FL
in DeLand, FL


Osteoarthritis of the Knee - NATIONWIDE
in NATIONWIDE,


Healthy Volunteers (Sleep Disorders) - DeLand FL
in DeLand, FL


ADHD in Children and Adolescents - NATIONWIDE
in NATIONWIDE,


 


© 1998-2008 Clinical Trials Home | Links | Terms And Conditions | Sitemap | Suggestion/Feedback
All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted nationwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.